Renin-angiotensin system (RAS) inhibitors, such as angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), are recommended as first-line drugs for hypertensive patients with diabetic nephropathy mainly for their blood pressure (BP)-lowering effects [1]. The gene discussed is ACE; the disease is diabetic kidney disease.